Related references
Note: Only part of the references are listed.Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
Jia Ruan et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
Christian H. Geisler et al.
BLOOD (2010)
Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group
Caroline Bodet-Milin et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Evaluation of the (R)VAD plus C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group
Remy Gressin et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
A. Goy et al.
ANNALS OF ONCOLOGY (2009)
Efficacy and Toxicity of 2 Schedules of Frontline Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Plus Bortezomib in Patients With B-Cell Lymphoma
Vincent Ribrag et al.
CANCER (2009)
Mantle cell lymphoma: state-of-the-art management and future perspective
Oliver Weigert et al.
LEUKEMIA & LYMPHOMA (2009)
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Eva Hoster et al.
BLOOD (2008)
The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival
Xiao Wang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I. Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
JE Romaguera et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG)
G Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
